Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Text messages may ease heart failure burden in ethiopia

NCT ID NCT07650474

Symptom relief Sponsor: Select College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a mobile-based telemedicine program—using phone calls and text messages for health education, medication reminders, and lifestyle advice—can improve quality of life in adults with chronic heart failure. About 70 patients in Ethiopia will be split into two groups: one receiving routine care plus mobile support, the other routine care only. After 8 weeks, researchers will compare changes in quality-of-life scores between the groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mobile-based telemedicine (phone calls and text messages for health education, medication reminders, lifestyle advice, and follow-up support)
What this could lead to
If it works, this could show that simple mobile support improves daily life and symptom control for heart failure patients, especially in low-resource settings.
What could go wrong
This is a small, early-stage study with only 72 participants, so results may not apply broadly. The intervention is short (8 weeks), and quality-of-life improvements may be modest or not last.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-65 years who will be diagnosed with CHF (NYHA class II⁃III) * Patients with reduced left ventricular ejection fraction LVEF ≤ 40% * Patient who will have access to a mobile phone and will be able to use it * Patients who will be able to communicate in Amharic, Oromic, or English * Patients who will provide written informed consent * Patients who will be diagnosed with HF lasting ≥ 6 months, to be confirmed by echocardiography and clinical assessment * Patients with no contraindications for mild to moderate physical activity Exclusion Criteria: * Patients with NYHA class IV or who will require intensive care at enrollment * Patients with other severe medical conditions (e.g., end-stage renal disease, \& end stage liver disease) * Patients with severe cognitive impairment or psychiatric illness that will interfere with participation * Patients already enrolled in another telemedicine or intervention study * Pregnant and lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic heart failure Health related quality of life

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Menelik II Comprehensive Specialized Hospital

    RECRUITING

    Addis Ababa, Ethiopia

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.